On the afternoon of May 25, 2022, Taicang City held a conference on the development of innovation clusters in the biopharmaceutical industry, and the Institute of Clinical Pharmacology Technology of Suzhou Industrial Technology Research Institute held a signing ceremony at the conference.

       Wu Tangchun, academician of Chinese Academy of Engineering and president of Tongji Medical College of Huazhong University of Science and Technology, attended the meeting in online form; Yue Jianmin, academician of Chinese Academy of Sciences and researcher of Shanghai Institute of Pharmaceutical Sciences, Chinese Academy of Sciences, sent a congratulatory letter to the meeting; Zhang Xiaohong, member of the Standing Committee of the Party Committee of Soochow University and vice president of Soochow University; Wang Xiangyuan, secretary of Taicang Municipal Party Committee; Qi Zhenyu, Wu Jingyu, Shi Jing, Han Biao, Wang Liping, Zhu Zhenxu, and Zhou Jianhui, leaders of Taicang; Xu Bo, deputy director of Suzhou Institute of Industry and Technology, attended the meeting. Xu Bo, Vice President of Suzhou Industrial Technology Research Institute, attended the meeting. Prof. Zhen Xuechu, Chairman of BioBiotech and Director of Institute of Clinical Pharmacology Technology of Suzhou Industrial Technology Research Institute, was invited to attend the meeting.

       The Institute of Clinical Pharmacology Technology of Suzhou Industrial Technology Research Institute (SITRI) is a tripartite joint venture between BioBee, Suzhou Industrial Technology Research Institute (SITRI) and Shaxi Town People's Government of Taicang City. The Institute will combine the resources of Taicang Biomedical Park, Soochow University, pharmaceutical companies, and the new GCP hospital in Suzhou to build a service platform for small molecule and large molecule clinical sample testing, a new base for phase I clinics, and a clinical trial center for specialty drugs, and will strive to build a comprehensive clinical research platform with the role of leading and demonstrating the industry, such as "drug clinical research + technical service + incubator". It strives to become a comprehensive clinical research platform with industry-leading and exemplary role of "drug clinical research + technical service + incubator".

       Professor Zhen Xuechu, Chairman of BE Biologicals and Director of the Institute of Clinical Pharmacology Technology of Suzhou Industrial Technology Research Institute, said that the Institute of Clinical Pharmacology Technology of Suzhou Industrial Technology Research Institute will become a comprehensive clinical research platform that gathers translational medicine, clinical research and development of pharmaceutical products, innovative technology services, and R&D and incubation, and will help Suzhou City's biomedical industry to strengthen the chain, make up for the chain, and extend the chain, and to become a first-class innovation center of the biomedical industry in the international arena.

       "The establishment of the Institute of Clinical Pharmacology Technology of Suzhou Industrial Technology Research Institute (SITRI) is the crystallization of the strategic cooperation between BioBio and SITRI, as well as the People's Government of Shaxi Town, Taicang City. 

In the future, BEE will continue to maintain and iterate its clinical trial professional service capabilities, promote the capacity building of clinical organizations in the region, facilitate the accelerated development of local enterprise innovation, and make positive contributions to the construction of a high-level biomedical industry innovation cluster in Suzhou.

About the Institute of Clinical Pharmacology Technology, Suzhou Industrial Technology Research Institute:

       The Institute of Clinical Pharmacology Technology of Suzhou Industrial Technology Research Institute is located in Taicang Industrial Park, covering an area of 30 acres, and is a technical service, innovation incubation and investment operation platform jointly built by BioBee, Suzhou Industrial Technology Research Institute and Shaxi Town People's Government of Taicang City.

       The Institute will gather global clinical research technology, projects and talent resources to build a clinical research system of international level, and provide one-stop nanny service for the whole chain, including: drug discovery, pharmaceutical research (GLP&GMP), preclinical research (GLP), clinical research (GCP), clinical sample production (GMP), and registration and reporting services.

       At the same time, the Institute will configure the operation and management team with diversified capabilities and experience, build an operation mechanism that meets the needs of modern enterprises and the market, introduce and incubate biomedical projects with core technologies, cultivate high-level innovative and entrepreneurial talents, promote the transfer and transformation of scientific and technological achievements, and help Suzhou build a landmark for the world-class biomedical industry, and become an internationally renowned "Pharmaceutical Valley of China", which is most representative of the domestic identification degree and has the most influence and competitiveness.